<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Shepherd, Frances A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">State of the Art Treatment for Lung Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">Four to six cycles of platinum-based doublet chemotherapy remains the standard treatment protocol for most patients with advanced non-small cell lung cancer (NSCLC). Longer treatment does not appear to increase overall or progression-free survival and may lead to toxicity issues and reduced quality of life. This article discusses the current state of knowledge concerning treatment for NSCLC patients without a targetable (driver) mutation, the impact of oncogenic drivers on treatment of NSCLC, as well as the use of maintenance therapy for patients with cancer as a way to delay disease progression and improve survival.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>